Abnova provides a fully integrated platform for high sensitivity and specificity quantification of COVID-19 neutralizing antibodies. It consists of neutralizing antibody blockade of lentivirus pseudotyped with COVID-19 spike (S) protein with luciferase (Luc) reporter gene interacting with ACE2 expressing 293T cells. Luc expression inside the ACE2 transfected stable 293T cells signifies viral entry and no neutralizing antibody blockade. In contrast, the absence of Luc expression signifies the presence of neutralizing antibody. Luc reporter system enables a high-sensitivity measurement of antibody neutralization. The platform’s specificity is determined by the pseudovirus S protein. Pseudovirus with different S proteins can constructed and generated for each COVID-19 variant (B1.1.7, B1.351, B., B.1.617.2, and B.1.1.529) to differentiate neutralizing antibodies targeting specific variants.

See Technology




Spike Protein Selection and Pseudovirus Production

  • Spike Protein cDNA Selection (SARS-CoV-2, B1.1.7, B1.351, B., B.1.617.2 and B.1.1.529)
  • Abnova’s Lentivirus Pseudotyped with S Protein (luciferase) and TCID50
  • Customer’s Pseudovirus (reporter gene) and TCID50



Target Cell Line Transfection

  • Abnova’s ACE2 Stable Transfected 293 T Cell Line
  • Customer’s ACE2 Transfected Cell Line



Neutralizing Antibody Assay Optimization and Testing



Certification and Report

  • Biosafety Level 2 Facility
  • Neutralizing Antibody Report








    • COVID-19 Monoclonal Antibody: Abnova has produced monoclonal antibodies, clone 7A7, 5D6, and 8C4, neutralizing SARS-CoV-2, B.1.1.529 variant



    • COVID-19 SAM Vaccine: Abnova has developed a COVID-19 SAM RBD (receptor-binding domain) formulated in lipid nanoparticle (LNP) which generates a higher antibody titer response than mRNA




For any inquiry, please contact : OEM@abnova.com